Clinical Trial Search

Primary: Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and…

Primary: Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks — 48; 50; 40; 60 units on a scale — p=>0.05

Primary: Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment — 5.2; 4.5 angina attacks per week — p=0.008

Primary: Seattle Angina Questionnaire (SAQ) — 68.09; 66.7; 58.4; 51.17 Units on scale

Primary: Coronary Flow Reserve — 1.6; 1.6; 1.9; 1.6 ratio

Primary: Seattle Angina Questionnaire Score — 83.3; 29.2; 74.1; 67.6 units on a scale

Primary: Change in Total Exercise Time (Seconds) — 24.3; 18.2; 33.9; 11.9 second

Primary: Number of Participants With Clinical Adverse Events (AEs) — 7; 1; 5 Participants

Primary: Percentage of Participants Without Sore Throat According to TSS Score — 84.35; 73.21; 13.91; 17.86 percentage of participants — p=0.028

Primary: Angina Episode Frequnecy — 2.28; 1.68 episodes per week

Primary: Change in Seattle Angina Questionnaire Score Regarding Angina Frequency — 0.70; 0.27 score on a scale

Primary: Change in Total Exercise Time — 450.39; 411.15 seconds — p=0.025

Primary: Number of Myocardial Ischemia Attacks in 24 Hours — 2.3; 3.8 ischemic attacks per 24 hours — p=<0.0001

Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…

Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058

Primary: Percentage of Patients Without Sore Throat According to the Tonsillopharyngitis Severity Score (TSS) — 89.47; 75.65; 7.02; 19.13 Percentage of Participants — p=0.00001

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants

Primary: Improve Angina Symptoms — 1.75 units on a scale — p=0.0013

Primary: QT Interval — 462.8 msec

Primary: Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B) — 0; 0; 1 Participants

Primary: Impact of Ranolazine on Hemoglobin A1C — -5; 2.6 percent change

Primary: Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12). — 330.60; 164.08 Relative change versus baseline (%)

Primary: Total Knowledge Score — 2.83; 4.0 knowledge score

Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05

Primary: Exercise Time on Treadmill — 28.4; 11.8 seconds

Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries

Primary: Number of Participants Assessed for Relative Change in the Index of Microcirculatory Resistance Before and After Ranolazine Therapy — 7 Participants

Primary: Changes in Quantitative Myocardial Perfusion Measured by Stress/Rest Cardiovascular Magnetic Resonance Imaging — 0.47; -0.16 ratio — p=0.001

Primary: Cardiac Magnetic Resonance (CMRs) — 11.7; 16.0 Percentage of ischemic myocardium

Primary: Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) Using the Modified Bruce Protocol — 108.7; 90.0 seconds